Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50742-0446-15 50742-0446 Carboplatin Carboplatin 150.0 mg/15mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 6, 2017 Feb 12, 2018 In Use
50742-0463-16 50742-0463 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sep 7, 2017 In Use
50742-0464-50 50742-0464 Leucovorin Calcium Leucovorin Calcium 10.0 mg/mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Nov 23, 2018 In Use
50742-0481-20 50742-0481 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec 21, 2019 In Use
50742-0482-50 50742-0482 fluorouracil FLUOROURACIL 2.5 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec 21, 2019 In Use
50742-0483-99 50742-0483 fluorouracil FLUOROURACIL 5.0 g/100mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec 21, 2019 In Use
71258-0015-02 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous Jul 30, 2018 In Use
50742-0512-20 50742-0512 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Sep 27, 2018 In Use
50742-0525-07 50742-0525 arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Jan 27, 2021 In Use
50881-0005-60 50881-0005 Ruxolitinib Jakafi 5.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0010-01 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
50881-0010-60 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
50881-0015-60 50881-0015 Ruxolitinib Jakafi 15.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0020-60 50881-0020 Ruxolitinib Jakafi 20.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0025-60 50881-0025 Ruxolitinib Jakafi 25.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0026-01 50881-0026 Pemigatinib PEMAZYRE 4.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
50881-0027-01 50881-0027 Pemigatinib PEMAZYRE 9.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
50881-0028-01 50881-0028 Pemigatinib PEMAZYRE 13.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
51144-0050-01 51144-0050 Brentuximab vedotin Adcetris 50.0 mg/10.5mL Immunotherapy Drug Antibody Conjugate CD30 Intravenous Aug 25, 2011 In Use
51285-0366-01 51285-0366 Methotrexate Trexall 5.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51285-0369-01 51285-0369 Methotrexate Trexall 15.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51655-0320-18 51655-0320 Prednisone Prednisone 20.0 mg/201 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Apr 29, 2014 In Use
51655-0320-30 51655-0320 Prednisone Prednisone 20.0 mg/201 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Apr 29, 2014 In Use
51655-0320-54 51655-0320 Prednisone Prednisone 20.0 mg/201 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Apr 29, 2014 In Use
51655-0400-43 51655-0400 Ondansetron HCL Ondansetron HCL 4.0 mg/31 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Mar 17, 2014 In Use

Found 11120 results — Export these results